Is HIMS Stock Still Undervalued After Settled Lawsuit?
Is Hims & Hers Health ($HIMS) is moving. With the Novo Nordisk lawsuit settled and a new partnership to distribute Wegovy and Ozempic, Barclays thinks this stock is undervalued and they just raised their price target to $29.
Updated Apr 08, 2026 | 12:18 PM EDT $HIMS could be the best comeback story so far this year...
Let me know what you think in the comments ⬇️
Subscribe to Chart Art
The best trade ideas and analysis from the Stocktwits community. Delivered daily by 8 pm ET.
Read about our editorial guidelines and ethics policy